Stattic

For research use only. Not for use in humans.

目录号：S7024

CAS No. 19983-44-9

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 730.64	现货
25mg	RMB 901.23	现货
50mg	RMB 1392.12	现货
100mg	RMB 2375.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Stattic发表文献184篇：

Nature, 2021, 600(7888):314-318

PubMed: 34819664 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(2):327-338

PubMed: 31928884 ( click the link to review the publication )

Nat Med, 2018, 24(5):563-571

PubMed: 29713085 ( click the link to review the publication )

Cell, 2017, 7;170(6):1134-1148.e10.

PubMed: 28886382 ( click the link to review the publication )

Nat Commun, 2022, 13(1):791

PubMed: 35145111 ( click the link to review the publication )

Int J Biol Sci, 2022, 18(4):1677-1694

PubMed: 35280699 ( click the link to review the publication )

Cancer Sci, 2022, 113(2):432-445

PubMed: 34927311 ( click the link to review the publication )

Front Pharmacol, 2022, 13:848355

PubMed: 35462928 ( click the link to review the publication )

Front Cardiovasc Med, 2022, 9:807298

PubMed: 35433880 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4566

PubMed: 34315881 ( click the link to review the publication )

J Cell Biol, 2021, 220(9)e202004114

PubMed: 34287648 ( click the link to review the publication )

J Neuroinflammation, 2021, 18(1):261

PubMed: 34749758 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01768-8

PubMed: 33824475 ( click the link to review the publication )

Cancer Lett, 2021, 519:328-342

PubMed: 34348188 ( click the link to review the publication )

Cancer Lett, 2021, 513:36-49

PubMed: 33991616 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5756

PubMed: 34228359 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):35

PubMed: 33736709 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Front Immunol, 2021, 12:630196

PubMed: 33897686 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:631163

PubMed: 33937232 ( click the link to review the publication )

J Neuroinflammation, 2021, 18(1):182

PubMed: 34419081 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(3):3443-3458

PubMed: 33428604 ( click the link to review the publication )

J Inflamm Res, 2021, 14:6619-6632

PubMed: 34908862 ( click the link to review the publication )
Am J Cancer Res, 2021, 11(12):5992-6003

PubMed: 35018238 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Transl Psychiatry, 2021, 11(1):298

PubMed: 34016951 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Biochem Pharmacol, 2021, 192:114688

PubMed: 34274354 ( click the link to review the publication )

Sci Rep, 2021, 11(1):21304

PubMed: 34716381 ( click the link to review the publication )

Gene, 2021, 812:146100

PubMed: 34864094 ( click the link to review the publication )

Genes Brain Behav, 2021, e12729

PubMed: 33641239 ( click the link to review the publication )

Cell Signal, 2021, 87:110141

PubMed: 34487815 ( click the link to review the publication )

Phytother Res, 2021, 10.1002/ptr.7117

PubMed: 34038010 ( click the link to review the publication )

Prostate, 2021, 81(8):452-462

PubMed: 33822400 ( click the link to review the publication )

Exp Cell Res, 2021, 408(1):112856

PubMed: 34597680 ( click the link to review the publication )

Gastroenterol Rep (Oxf), 2021, 9(1):59-70

PubMed: 33747527 ( click the link to review the publication )

J Periodontol, 2021, 10.1002/JPER.21-0290

PubMed: 34709660 ( click the link to review the publication )

Cancer Immunol Res, 2021, 10.1158/2326-6066.CIR-21-0124

PubMed: 34933913 ( click the link to review the publication )

Blood Adv, 2021, 5(14):2863-2878

PubMed: 34297045 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-611538/v1

PubMed: None ( click the link to review the publication )

PLoS Pathog, 2021, 17(2):e1009303

PubMed: 33529218 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 30;9. pii: e51317

PubMed: 32223889 ( click the link to review the publication )

J Hematol Oncol, 2020, 5;13(1):68

PubMed: 32503584 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32150944 ( click the link to review the publication )

Cell Death Discov, 2020, 2;6:42

PubMed: 32528731 ( click the link to review the publication )
J Mol Cell Biol, 2020, 1 pii: mjaa011

PubMed: 32236560 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):505

PubMed: 33246502 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Oxid Med Cell Longev, 2020,

PubMed: 32855767 ( click the link to review the publication )

J Am Heart Assoc, 2020, 9(18):e017071

PubMed: 32865099 ( click the link to review the publication )

Front Oncol, 2020, 5;10:652

PubMed: 32432040 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15563

PubMed: 32618105 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30632-8

PubMed: 33359364 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 69(1):115-126

PubMed: 31802182 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Cell Mol Neurobiol, 2020, 18

PubMed: 32424774 ( click the link to review the publication )

Invest New Drugs, 2020, 20

PubMed: 32436058 ( click the link to review the publication )

Life Sci, 2020, 242:117221

PubMed: 31881224 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

PLoS One, 2020, 15(11):e0242337

PubMed: 33180876 ( click the link to review the publication )

Int J Oral Sci, 2020, 12(1):38

PubMed: 33380723 ( click the link to review the publication )

Hum Exp Toxicol, 2020, 39(2):224-234

PubMed: 31610697 ( click the link to review the publication )

Exp Clin Endocrinol Diabetes, 2020, 10.1055/a-0998-7985

PubMed: 31896157 ( click the link to review the publication )

Pharmacol Res, 2020, 153:104661

PubMed: 31982491 ( click the link to review the publication )

J Cell Physiol, 2020, 235(2):1076-1089

PubMed: 31276203 ( click the link to review the publication )

Cell Signal, 2020, 65:109413

PubMed: 31494257 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):116-125

PubMed: 32123861 ( click the link to review the publication )
Front Immunol, 2020, 11:2031

PubMed: 33042115 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30190-9

PubMed: 33238220 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3129-3143

PubMed: 32913557 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106143

PubMed: 32062080 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):531

PubMed: 32661236 ( click the link to review the publication )

Nat Commun, 2019, 10(1):716

PubMed: 30755611 ( click the link to review the publication )

Biomaterials, 2019, 219:119371

PubMed: 31352310 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):40

PubMed: 30866952 ( click the link to review the publication )

Diabetes, 2019, 68(6):1303-1314

PubMed: 30936144 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Redox Biol, 2019, 20:451-457

PubMed: 30439686 ( click the link to review the publication )

Brain Behav Immun, 2019, 81:228-246

PubMed: 31207335 ( click the link to review the publication )

J Pathol, 2019, 248(4):438-451

PubMed: 30900255 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

EBioMedicine, 2019, 39:132-144

PubMed: 30528455 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846806

PubMed: 31205504 ( click the link to review the publication )

Cell Biol Toxicol, 2019, 10.1007/s10565-019-09471-x

PubMed: 30941654 ( click the link to review the publication )

Kidney Blood Press Res, 2019, 44(6):1453-1464

PubMed: 31722339 ( click the link to review the publication )

Oncogenesis, 2019, 8(8):39

PubMed: 31311917 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31019895 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30787154 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31575039 ( click the link to review the publication )
J Clin Periodontol, 2019, 10.1111/jcpe.13166

PubMed: 31286538 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:1309-1319

PubMed: 30804683 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 380:114698

PubMed: 31394157 ( click the link to review the publication )

Cytokine, 2019, 119:81-89

PubMed: 30903867 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5315-5325

PubMed: 30320916 ( click the link to review the publication )

Neuroscience, 2019, 416:198-206

PubMed: 31374230 ( click the link to review the publication )

Int J Oncol, 2019, 10.3892/ijo.2019.4880

PubMed: 31545422 ( click the link to review the publication )

Cancer Med, 2019, 8(17):7345-7358

PubMed: 31631559 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:1137-1146

PubMed: 30809095 ( click the link to review the publication )

Scand J Immunol, 2019, 89(6):e12761

PubMed: 30977163 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2019, 2019:3909468

PubMed: 31485245 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3803-3808

PubMed: 31262907 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(6):152392

PubMed: 30922625 ( click the link to review the publication )

Am J Nucl Med Mol Imaging, 2019,

PubMed: 31976162 ( click the link to review the publication )

Immunity, 2018, 48(4):787-798

PubMed: 29653697 ( click the link to review the publication )

Circulation, 2018, 30;138(18):2021-2035

PubMed: 29967195 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6236-6247

PubMed: 30131384 ( click the link to review the publication )

Blood Cancer J, 2018, 8(2):20

PubMed: 29440639 ( click the link to review the publication )

Cancer Lett, 2018, 436:52-62

PubMed: 30118844 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):375

PubMed: 29515107 ( click the link to review the publication )
Cell Death Dis, 2018, 9(5):501

PubMed: 29717134 ( click the link to review the publication )

Front Immunol, 2018,

PubMed: 29867938 ( click the link to review the publication )

Front Immunol, 2018, 9:1263

PubMed: 29930553 ( click the link to review the publication )

Mol Oncol, 2018, 12(7):1203-1215

PubMed: 29791786 ( click the link to review the publication )

Carcinogenesis, 2018, 39(9):1165-1175

PubMed: 29893810 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(3):489-501

PubMed: 29637003 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(2):436-442

PubMed: 29288671 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(11):1057-1064

PubMed: 30277836 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

Int Immunopharmacol, 2018, 58:136-144

PubMed: 29587202 ( click the link to review the publication )

Transl Oncol, 2018, 11(2):487-497

PubMed: 29494948 ( click the link to review the publication )

Int J Mol Med, 2018, 42(1):497-504

PubMed: 29620257 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2018, 22(19):6308-6314

PubMed: 30338828 ( click the link to review the publication )

Scand J Immunol, 2018, 88(3):e12703

PubMed: 30047999 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )

Tumour Biol, 2018, 40(1):1010428317731369

PubMed: 29320977 ( click the link to review the publication )

Prostaglandins Other Lipid Mediat, 2018, 138:31-40

PubMed: 30110652 ( click the link to review the publication )

Circ Res, 2017, 121(6):617-627

PubMed: 28743805 ( click the link to review the publication )

Oncogene, 2017, 36(48):6725-6737

PubMed: 28783177 ( click the link to review the publication )

Mol Ther Oncolytics, 2017, 6:90-99

PubMed: 28875159 ( click the link to review the publication )

Cell Death Dis, 2017, 8(4):e2725

PubMed: 28383559 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

J Mol Med (Berl), 2017, 95(2):221-233

PubMed: 27709266 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(3):433-447

PubMed: 28401002 ( click the link to review the publication )
Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11540

PubMed: 28912535 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):980-986

PubMed: 28284718 ( click the link to review the publication )

Cell Signal, 2017, 32:48-58

PubMed: 28093267 ( click the link to review the publication )

Toxicol In Vitro, 2017, 45(Pt 1):10-18

PubMed: 28739487 ( click the link to review the publication )

Int J Mol Med, 2017, 40(5):1549-1556

PubMed: 28949390 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0178844

PubMed: 28636670 ( click the link to review the publication )

Gene, 2017, 627:114-122

PubMed: 28603075 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(7):7466-7474

PubMed: 31966590 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29100353 ( click the link to review the publication )

Sci Rep, 2017, 10.1038/srep41404

PubMed: 28112250 ( click the link to review the publication )

Oncotarget, 2017, 8(37):61876-61889

PubMed: 28977911 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31227-31237

PubMed: 28415722 ( click the link to review the publication )

Leukemia, 2016, 30(6):1311-9

PubMed: 26854024 ( click the link to review the publication )

Cell Rep, 2016, 15(3):460-470

PubMed: 27068459 ( click the link to review the publication )

EBioMedicine, 2016, 8:132-149

PubMed: 27428425 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2294

PubMed: 27415424 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(7 Pt A):1579-88

PubMed: 27066979 ( click the link to review the publication )

Int J Cardiol, 2016, 210:85-92

PubMed: 26930642 ( click the link to review the publication )

Cancer Prev Res (Phila), 2016, 9(8):657-63

PubMed: 27267892 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2010-2023

PubMed: 26663388 ( click the link to review the publication )

Int J Oncol, 2016, 48(1):161-72

PubMed: 26549725 ( click the link to review the publication )
J Physiol Sci, 2016, 66(3):229-39

PubMed: 26541157 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Antioxid Redox Signal, 2015, 24(2):70-83

PubMed: 26154696 ( click the link to review the publication )

Neoplasia, 2015, 17(7):586-97

PubMed: 26297436 ( click the link to review the publication )

Transl Res, 2015, 166(4):384-98

PubMed: 25843671 ( click the link to review the publication )

Hum Pathol, 2015, 46(2):284-94

PubMed: 25537973 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: 25436422 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0128406

PubMed: 26010889 ( click the link to review the publication )

J Interferon Cytokine Res, 2015, 10.1089/jir.2014.0128

PubMed: 25919795 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3681-y

PubMed: 26124007 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8244-54

PubMed: 25749519 ( click the link to review the publication )

J Exp Med, 2015, 212(12):2147-63

PubMed: 26552708 ( click the link to review the publication )

Tumour Biol, 2015, 36(12):9475-86

PubMed: 26124007 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

特性

Stattic是第一个非肽类小分子，抑制STAT3 SH2结构域的功能，无论在体外STAT3磷酸化状态。

靶点

STAT3 ^[1]
(Cell-free assay)

5.1 μM

体外研究

Stattic抑制gp130受体衍生的含磷酸化酪氨酸的肽结合到STAT3 SH2结构域，这种作用存在强烈的温度依赖性。Stattic对酪氨酸磷酸化的肽结合到酪氨酸激酶Lck的SH2结构域只有很微弱的作用效果。Stattic不抑制其他两个二聚体转录因子(c-Myc/Max 和 Jun/Jun)的二聚化。Stattic抑制荧光素标记的磷酸化肽段结合到STAT1和STAT5b的SH2域。Stattic浓度为10 μM，选择性抑制DNA与STAT3二聚体结合。Stattic抑制STAT3在Tyr705位点磷酸化，而对STAT1在Tyr701(HepG2细胞)位点磷酸化或 JAK1, JAK2, 和c-Src(MDA-MB-231和MDA-MB-235S细胞)磷酸化几乎没有抑制效果。Stattic增加STAT3依赖性的乳腺癌细胞系的凋亡率。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H9c2	NXHOTWM{TnWwY4Tpc44hSXO\|YYm=	NITa[IoyOOLCid88US=>	Mn7nOQKBkWh?		MnjFdoV3\XK\|ZYOgeIhmKGWoZnXjeJMhd2ZiSVytNlc>	MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|M{m2N\|MoRjJ4M{O5OlM{RC:jPh?=
NPC	NVq1THVGTnWwY4Tpc44hSXO\|YYm=	NGnGOpMxNTdwNTFCuW0>			NIrycZJi[m:uaYPo[ZMhTU2WLXzpb4UhdW:uZXP1cIFzKGGudHXyZZRqd26\|LDDhcoQh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9vKGmwZIXj[YQh[nliUlvJVEBsdm:la3Tve44>	Mn\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUW0N\|AoRjJ3OUG1OFMxRC:jPh?=
HASMC	Ml\SSpVv[3Srb36gRZN{[Xl?	NUO2NmFIOS5{NT21JO69VQ>?	NX35[VN2OjBibXnu	M4\ZN2ROW00EoB?=	MkfDbY5pcWKrdIOgdE0pYSlvU2TBWE0yNDNuNTDzbYdv[Wy\|wrC=	MkPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NEm2NlIoRjJ3OES5OlIzRC:jPh?=
H9c2	NF;2R3FHfW6ldHnvckBCe3OjeR?=	NXz6RZVHOi9zMDFOwG0>	NVrhZm81OiCq	MnPISG1UV8Li	MnPxZYJzd2ejdHXzxsB1cGViY4n0c5Bzd3SnY4TpeoUh\W[oZXP0d{Bw\iCLTD2yO{Bi\2GrboP0JHNJ	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh{MEmwO{c,OjV6MkC5NFc9N2F-
A431	NVHtNIhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7sO4YzyqEQvF2=	MofFNuKhcA>?		M{n4RYJtd2OtczDFS2YuemW4ZYLz[YQh\GWlcnXhd4V{KGmwIHPlcIwhfmmjYnnsbZR6	NIq5foI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyNFQ{PSd-MkW3NlA1OzV:L3G+
A431	M1j2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NES0W3kzyqEQvF2=	MnizNuKhcA>?		M3nkTIlv[3KnYYPld{BqdiCjcH;weI9{cXNiaX7keYNm\CCkeTDzbIlsd26rbh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{MESzOUc,OjV5MkC0N\|U9N2F-
SiHa	NX7MPZV5S2WubDDWbYFjcWyrdImgRZN{[Xl?	NILCW2I2NTd3IH7N	MoLkNlTDqGkEoB?=		NHr3V5V{cG:5czDtc5JxcG:ub3f5JI9nKGFidInwbYNidCCjcH;weI91cWNiY3XscEBidmRiZH;z[U1l\XCnbnTlcpQhdG:\|czDv[kBk\WyuII\pZYJqdGm2edMg	Mke1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{m2OFQoRjJ3NUO5OlQ1RC:jPh?=
SiHa	M3TqNWZ2dmO2aX;uJGF{e2G7	M1LiUlUuPzVibl2=	MX6yOOKhcMLi		MmLmdoVlfWOnczD0bIXDqHCqb4PwbI9zgWyjdHnvckBifCC2aHWgeJlzd3OrbnWgdoV{cWS3ZTC3NFXDqA>?	NYHiRVllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|k3PDRpPkK1OVM6PjR2PD;hQi=>
ECA109	NX\pdHRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq4eWFbOC1{MDFOwG0>	M{jwO\|I1yqCqwrC=		NEHCfplKSzVyPUWuOVAh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
TE13	M4D4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoruNE0zOCEQvF2=	NXjFd2t6OjUEoHlCpC=>		MlOxTWM2OD14LkG1xsDPxE1?	MonhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
KYSE150	NXf4TWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DTfVAuOjBizszN	NHnlW5MzPMLiaNMg		Ml7FTWM2OD1zMj62OOKh\|ryP	NU[1TopvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVI1QDBpPkK1OFkzPDhyPD;hQi=>
ECA109	NXTQNHc5S2yxbn;n[Y5q[yCVdYL2bZZidCCDc4PhfS=>	Mo\FNE42yqEQvF2=	NXn5fFQ5OjUEoHlCpC=>		NVXFO5U3e3WycILld5NmeyC2aHWgZ4xwdm:pZX7pZ{Bnd3KvYYTpc44>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
TE13	NVixU2NtS2yxbn;n[Y5q[yCVdYL2bZZidCCDc4PhfS=>	NF7OUXkxNjYEoN88US=>	NH;MPZQzPMLiaNMg		NYD5d4Vze3WycILld5NmeyC2aHWgZ4xwdm:pZX7pZ{Bnd3KvYYTpc44>	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
KYSE150	MojVR4xwdm:pZX7pZ{BUfXK4aY\hcEBCe3OjeR?=	M3HDelAvPcLizszN	NUHFNVNnOjUEoHlCpC=>		MorRd5VxeHKnc4Pld{B1cGViY3zvco9o\W6rYzDmc5Ju[XSrb36=	NITvWpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NlQ5OCd-MkW0PVI1QDB:L3G+
ECA109	MX\GeY5kfGmxbjDBd5NigQ>?	MUSwMlXDqM7:TR?=	M4HOR\|I1yqCqwrC=		MXXlcohidmOnczDJVk1qdmS3Y3XkJIdmdmW{YYTpc44hd2ZiRGPCdy=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
PC3M-1E8	MnnhSpVv[3Srb36gRZN{[Xl?	MViyMlUwPS9zMDFOwG0>	NETocY4xNTRiaB?=		M1jKT4lvcGmkaYTzJJRp\SCVVFHUN{Bi[3SrdnH0bY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi	MojlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkGzOlUoRjJ3Mk[xN\|Y2RC:jPh?=
PC3M-1E8	MkjVSpVv[3Srb36gRZN{[Xl?	MYmxNEDPxE1?	NHfJPFIzPCCq		MkjI[I94dnKnZ4XsZZRmeyCEY3ytfGwtKHO3co\peolvKGGwZDDjMW16[w>?	M2PzNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[xN\|Y2Lz5{NUK2NVM3PTxxYU6=
PC3M-1E8	MnHZSpVv[3Srb36gRZN{[Xl?	M3LiSVExKM7:TR?=	NUfDSo1sOjRiaB?=		M3\Vc4lvcGmkaYTzJGlNNTZiaX7keYNm\CCVVFHUN{Bi[3SrdnH0bY9vKGGwZDD0bIUhUUxvNj3pcoR2[2WmIGPURXQ{KGGldHn2ZZRqd25?	NIfGRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2NVM3PSd-MkWyOlE{PjV:L3G+
PC3M-1E8	M4L0b2Ntd26xZ3XubYMhW3W{dnn2ZYwhSXO\|YYm=	Mk[xNk42NzVxMUCg{txO			MUXpcohq[mm2c9MgeIhmKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueR?=	M363NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[xN\|Y2Lz5{NUK2NVM3PTxxYU6=
MDA-MB-231	MkPBSpVv[3Srb36gRZN{[Xl?	NVToT2w1OjBizszN	M3TVfVIhcA>?		MX3lfIhq[mm2czDTcoFqdCCjbnSgSU1k[WSqZYLpckBmgHC{ZYPzbY9v	MonSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUOzOFkoRjJ3MUWzN\|Q6RC:jPh?=
H9c2	NH[zVpBHfW6ldHnvckBCe3OjeR?=	NFTRdlUzOCEEtV2=	M1W2V\|MxKG2rbh?=	NGn2[pRFVVORwrC=	MYXhZo9tcXOqZYOgdJJweG:ob3ytbY5lfWOnZDDBT3QheGixc4Doc5J6dGG2aX;uJIF1KGKxdHigd4VzPDd\|IHHu[EB1cHJ\|MEi=	NELVUVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOVA3Pyd-MkWxNFUxPjd:L3G+
HaCaT	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7SSHEyOCEEtV2=	MYeyNEBucW5?	M3T2[WROW00EoB?=	Ml7a[Y5p[W6lZYOgd49z[W[nbnniMUBidmRic4XubZRqdmmkLXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25?	NHfSe\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxN\|kxPyd-MkWwNVM6ODd:L3G+
Caki-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXLTIZuOTBiwsXN	MmH3NlAhdWmw	MVHEUXNQyqB?	MVvlcohidmOnczDzc5Ji\mWwaXKtJIFv\CC\|dX7peIlvcWJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>?	NYPQcYFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVM6ODdpPkK1NFE{QTB5PD;hQi=>
HaCaT	NH;yRVdCeG:ydH;zbZMhSXO\|YYm=	MW[xNEDDvU1?	MX[yNEBucW5?	M4nKdWROW00EoB?=	M2\P[4lv[3KnYYPld{Bxem:yb4L0bY9veyCxZjDhdI9xfG:2aXOgZ4VtdHNiZIXlJJRwKHS{ZXH0cYVvfCC5aYToJJNwemGoZX7pZkBweiC\|dX7peIlvcWJ?	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUO5NFcoRjJ3MEGzPVA4RC:jPh?=
FHL-primed hNSCs	NHXVT4lE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MnPiNE4xOi13IN88US=>	NH7PUJE4OiCq		NUXmcnNqdGWjZIOgeI8hfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[XRiaHnnbEBkd26lZX70doF1cW:w	M1TufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS1OFM1Lz5{NEm0OVQ{PDxxYU6=
ELL-primed hNSCs	NGqw[ZVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mnz2NE4xOi13IN88US=>	M4PMT\|czKGh?		MYjs[YFleyC2bzD0bIUhdG:\|czDv[kBk\WyuII\pZYJqdGm2eTDheEBpcWeqIHPvcoNmdnS{YYTpc44>	NGTpOGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OVQ{PCd-MkS5OFU1OzR:L3G+
SS	NYryW\|JoS2WubDDWbYFjcWyrdImgRZN{[Xl?	MmDUNU0yOCEQvF2=	NGnMbnM4OiCq	M3fRSWROW09?	MneyZ4F2e2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7obYJqfGmxbjDv[kB1cGVidnnhZoltcXS7wrC=	M3K5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W2NVEyLz5{NEe1OlEyOTxxYU6=
SeAx	M4LqXmNmdGxiVnnhZoltcXS7IFHzd4F6	MXSxMVExKM7:TR?=	NXj5UpdlPzJiaB?=	M3jFeGROW09?	MoD5Z4F2e2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7obYJqfGmxbjDv[kB1cGVidnnhZoltcXS7wrC=	M2TZNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W2NVEyLz5{NEe1OlEyOTxxYU6=
HuT-78	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NU[yPIMxOS1zMDFOwG0>	NWXhTZNxPzJiaB?=	NH;m[XZFVVOR	M2D3[4NifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnubIljcXSrb36gc4YhfGinII\pZYJqdGm2edMg	NGDtVow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1OlEyOSd-MkS3OVYyOTF:L3G+
CD4+	NVfCUFZ1SXCxcITvd4l{KEG\|c3H5	NWDY[ZVuOTEkgJpOwI0>	MlHpNlQhcA>?	M3rRNWROW09?	M{jOV4lv\HWlZYOgZZBweHSxc3nzJJN1em:wZ3z5	Mn;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NU[xNVEoRjJ2N{W2NVEyRC:jPh?=
MCF-7	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f5TFAvPDZ7LUOuO\|Uh\|ryP	NUXWXYt7PSCm		Ml7adoVlfWOnczDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7	NVHKT5hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlgxPzhpPkK0O\|I5ODd6PD;hQi=>
MCF-7/LCC1	MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zMc\|AvPDZ7LUOuO\|Uh\|ryP	M2HHRVUh\A>?		MnjadoVlfWOnczDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7	MlfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkiwO\|goRjJ2N{K4NFc5RC:jPh?=
MCF-7/LCC9	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[3cnIxNjR4OT2zMlc2KM7:TR?=	MXm1JIQ>		MVXy[YR2[2W\|IHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl?	MoPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkiwO\|goRjJ2N{K4NFc5RC:jPh?=
HaCaT	NXrtVXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2j3VFExKML3TR?=	MUOyNEBucW5?	NGe5VnpFVVORwrC=	NELQWXBmdmijbnPld{BmfmW{b3zpcZV{NWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{GzNUc,OjR2MkOxN\|E9N2F-
HaCaT	NYLiOVhPSXCxcITvd4l{KEG\|c3H5	MnTCNVAhyrWP	Ml7ENlAhdWmw	Mnf2SG1UV8Li	MVnlcohidmOnczD0bIUh[XCxcITveIlkKGWoZnXjeJMhd2ZiZY\ldo9tcW23cx?=	Mnf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkOxN\|EoRjJ2NEKzNVMyRC:jPh?=
MDA-MB-231	NGC3[nZHfW6ldHnvckBCe3OjeR?=	NULIfWY6OTBiwsXN	MmDzNlQhcA>?	NGXjZ4VFVVORwrC=	MnWydoVlfWOnczDQMXNVSVR\|IHX4dJJme3Orb36=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5NkW4Okc,OjR\|N{[1PFY9N2F-
SUM-159	MXfGeY5kfGmxbjDBd5NigQ>?	NITON5AyOCEEtV2=	NHnXdXYzPCCq	MYLEUXNQyqB?	NVTJR4JRemWmdXPld{BRNVOWQWSzJIV5eHKnc4Ppc44>	M{CyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{e2OVg3Lz5{NEO3OlU5PjxxYU6=
SK-BR-3	NW\Qb5ZMTnWwY4Tpc44hSXO\|YYm=	NX\2OZJZOTBiwsXN	M3jBWFI1KGh?	NFu0T\|FFVVORwrC=	M4H2TpJm\HWlZYOgVE1UXEGWMzDlfJBz\XO\|aX;u	MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|N{[1PFYoRjJ2M{e2OVg3RC:jPh?=
MCF7-HER2	NYnlRZlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPUXW0xNTFyIN88US=>	MVy0PEBp	M4HIU2ROW09?	MljrbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{WwPEc,OjR{OUe1NFg9N2F-
MCF7-HER2	Mn30SpVv[3Srb36gRZN{[Xl?	MVi1JO69VQ>?	NGHGdHczPCCq	M133fWROW09?	Mknh[IlucW6rc3jld{BUd3hvMjygU4N1NTRuIHHu[EB{dHWpIHX4dJJme3Orb36=	MoDXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NFgoRjJ2Mkm3OVA5RC:jPh?=
MCF7-HER2	NYLsVXZCTnWwY4Tpc44hSXO\|YYm=	NHTsU4o2KM7:TR?=	M4LVOlI1KGh?	M{HMTWROW09?	NIDZTFZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGVOXCCvYYLr[ZJ{NCC4aX3lcpRqdiCjbnSgd4x2\w>?	M3n6SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
MCF7-HER2	NIfFSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGKwNGs2KM7:TR?=	NGPwcpYzPCCq	NIjCSVFFVVOR	Ml\x[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiClb33ibY5m\CC5aYToJGhmemOncITpci=>	M4XCTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
HMECs	MmPkSpVv[3Srb36gRZN{[Xl?	Ml[3NVAh\|ryP	NV:0N\|d[OiCq		NWPkRmIxcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTygV3RCXDJiYX7kJHNVSVR\|	M2HXdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN\|I4Lz5{NEKxNVMzPzxxYU6=
HTR8/SVneo	MXHGeY5kfGmxbjDBd5NigQ>?	MnjONeKh\|ryPwrC=	MV:xxsBp		NY\SSY1we3WycILld5Nm\CCRU12tbY5lfWOnZDDTWGFVOyCyaH;zdIhwenmuYYTpc44>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4MEK0NUc,OjRyNkCyOFE9N2F-
HTR8/SVneo	NFq1[GZHfW6ldHnvckBCe3OjeR?=	MnPuNE42NzIEoN88UeKh	NH;KSHk1QCCq		NVXzOohNemW\|dH;y[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiC\|dYDwdoV{e2WmIHL5JG9UVQ>?	MlzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkCyOFEoRjJ2ME[wNlQyRC:jPh?=
HTR8/SVneo	NGTrVI9HfW6ldHnvckBCe3OjeR?=	M1rHbVHDqM7:TdMg	NUjwdoNvPDhiaB?=		M4DhepNq\26rZnnjZY51dHliaX7jdoVie2W\|IH3p[5JifGmxbjDifUBQW04EoB?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4MEK0NUc,OjRyNkCyOFE9N2F-
C13*	NFLVN2FCeG:ydH;zbZMhSXO\|YYm=	NVnrcmFpOC1zMDFOwG0>	MVuyOE81QCCq		Mln5bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NF;UdWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlU2QCd-MkO5OlI2PTh:L3G+
OV2008	NHXiNmxCeG:ydH;zbZMhSXO\|YYm=	MWCwMVExKM7:TR?=	MYiyOE81QCCq		MmXEbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
C13*	Mni0RZBweHSxc3nzJGF{e2G7		MUCyOE81QCCq		NVy5fJhx\W6qYX7j[ZMh[2m\|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK1OVgoRjJ\|OU[yOVU5RC:jPh?=
OV2008	MVPBdI9xfG:\|aYOgRZN{[Xl?		M1PxV\|I1NzR6IHi=		Mlfs[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	NVLjbVFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlI2PThpPkKzPVYzPTV6PD;hQi=>
W480	NEX6TGtHfW6ldHnvckBCe3OjeR?=	NIHrTlYzNjVxMUCg{txO	NYLqfFZVOzBibXnu	M2f4dWROW09?	NVixUm1pe2Wwc3n0bZpmeyClZXzsd{B1dyClaHXtc5Ji\GmxdHjldoFxgSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	Mm[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{S5O\|IoRjJ\|OUO0PVczRC:jPh?=
SW837	NFHrOnlHfW6ldHnvckBCe3OjeR?=	M3nnbVIvPS9zMDFOwG0>	MUOzNEBucW5?	MkXRSG1UVw>?	NUDSeW1Xe2Wwc3n0bZpmeyClZXzsd{B1dyClaHXtc5Ji\GmxdHjldoFxgSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NW\aNY1URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|Q6PzJpPkKzPVM1QTd{PD;hQi=>
T24	MnH6SpVv[3Srb36gRZN{[Xl?	M1zQPVIwOTBxMkCg{txO	MlTCNlQhcA>?		MUTjZZV{\XNiZH;z[U1l\XCnbnTlcpQhcW6qaXLpeIlwdiCxZjD0bIUhS1iFTEGyMYlv\HWlZXSgbY5kemWjc3Wgc4YhcW64YXTpcoch[2WubIO=	MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Mk[wO\|koRjJ\|NUK2NFc6RC:jPh?=
CNE1	M4TBT2Z2dmO2aX;uJGF{e2G7	M1jYTVIxKML3TR?=	M3TwS\|Q5KGh?		MX\icI9kc3NidHjlJGlNNTZiaX7jdoVie2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTeIF1Ow>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	MYHGeY5kfGmxbjDBd5NigQ>?	MUWyNEDDvU1?	M2i2NFQ5KGh?		MVXicI9kc3NidHjlJGlNNTZiaX7jdoVie2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTeIF1Ow>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
HONE1	NGftdYpHfW6ldHnvckBCe3OjeR?=	MUWyNEDDvU1?	NF;GT3I1QCCq		MYTicI9kc3NidHjlJGlNNTZiaX7jdoVie2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTeIF1Ow>?	NWm2cZk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
CNE1	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDvfYQ1KM7:TR?=			MVzzbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubDD2bYFjcWyrdIm=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE1	MkHjSpVv[3Srb36gRZN{[Xl?	NY\CPWp{OC1{MDFOwG0>	MWmwMVQhcA>?		M132VolvcGmkaYTzJHN1[XR\|IHHjeIl3[XSrb36gbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	M4LOVmZ2dmO2aX;uJGF{e2G7	MYKwMVIxKM7:TR?=	M4PuXVAuPCCq		MV\pcohq[mm2czDTeIF1OyCjY4TpeoF1cW:wIHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	M4TNb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
HONE1	MnT6SpVv[3Srb36gRZN{[Xl?	NH;rTYYxNTJyIN88US=>	M1;OUVAuPCCq		MlG4bY5pcWKrdIOgV5RifDNiYXP0bZZifGmxbjDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE1	NUfrbGxRS2WubDDWbYFjcWyrdImgRZN{[Xl?	MXWwMlUuPjRizszN	M37vUVQ5KGh?		M1XUUZN2eHC{ZYPz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	M3rRVmNmdGxiVnnhZoltcXS7IFHzd4F6	Mk[xNE42NTZ2IN88US=>	MXS0PEBp		MXjzeZBxemW\|c3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
HONE1	M3Hs[GNmdGxiVnnhZoltcXS7IFHzd4F6	NFi4SYwxNjVvNkSg{txO	NFezTXQ1QCCq		NGDid3N{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	M{n2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
C666-1	M3z5TmNmdGxiVnnhZoltcXS7IFHzd4F6	NIL6UpcxNjVvNkSg{txO	M3GxWVQ5KGh?		NFixUWR{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	MkTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
CNE1	M3;5bWFxd3C2b4Ppd{BCe3OjeR?=	NVWx[ll3OTBiwsXNxsA>	MmK2OFghcA>?		MkLtbY5lfWOnczDhdI9xfG:\|aYRCpC=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	NHTpZ\|BCeG:ydH;zbZMhSXO\|YYm=	M3fsN\|ExKML3TdMg	M4\jN\|Q5KGh?		NI\WOWZqdmS3Y3XzJIFxd3C2b4Ppd:Kh	NEDlWGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
HONE1	MlLORZBweHSxc3nzJGF{e2G7	M4\KU\|ExKML3TdMg	MWW0PEBp		M2ntNIlv\HWlZYOgZZBweHSxc3nzxsA>	MlToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
CNE2	NIHqXG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEnpUIcyNzJizszN	NHP2Z\|c1QCCq		NV7reHNxe2Wwc3n0bZpmKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	Mn;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
HONE1	NHjlWXJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3\rbVEwOiEQvF2=	M3XJRVQ5KGh?		NILYUWV{\W6\|aYTpfoUh[2WubIOgeI8hemGmaX;0bIVz[XC7	NHP3OJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
C666-1	NGP1ZVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXH3Z2JrOS9{IN88US=>	NGXpRpo1QCCq		NUfUdYx5e2Wwc3n0bZpmKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	NU\INnNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HEC-1A	NFXJWppHfW6ldHnvckBCe3OjeR?=	M3\mXFHDqM7:TdMg	M1\0cVI1KGh?	MYrEUXNQ	M1q3RoJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KDFyJTDGRnM>	NYPUTYJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlIzODhpPkKzNlYzOjB6PD;hQi=>
RL95-2	NGS3RVNHfW6ldHnvckBCe3OjeR?=	NX3nbJNDOcLizszNxsA>	NWPGdJBtOjRiaB?=	NUP3XJJwTE2VTx?=	M{TtfYJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KDFyJTDGRnM>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4MkKwPEc,OjN{NkKyNFg9N2F-
HEC-1A	NXroeIc5TnWwY4Tpc44hSXO\|YYm=	NFPBTGkyyqEQvF5CpC=>	MVWyOEBp	M4e0XGROW09?	NFW0SVJjdG:la4OgeIhmKE2XQ{KwMYVvcGGwY3XkJIlvfmG\|aX;uJJRzcWepZYLl[EBjgSCHR1dCpC=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4MkKwPEc,OjN{NkKyNFg9N2F-
RL95-2	M1z5SWZ2dmO2aX;uJGF{e2G7	M1z4b\|HDqM7:TdMg	NX\TZYdlOjRiaB?=	NUfsW5dYTE2VTx?=	NWj5U2lp[myxY3vzJJRp\SCPVVOyNE1mdmijbnPl[EBqdn[jc3nvckB1emmpZ3Xy[YQh[nliRVfGxsA>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4MkKwPEc,OjN{NkKyNFg9N2F-
CT26	NYHB[IRkTnWwY4Tpc44hSXO\|YYm=	NHS5Z5ozOCCvTR?=	NV3Td3lROSCq		MWTzeZBxemW\|c3XzJGhITi2rbnT1Z4VlKF[HR1[g[ZhxemW\|c3nvcuKh	M3LDWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkOzNVY{Lz5{M{KzN\|E3OzxxYU6=
UM-SCC-17B	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3WTWM2OD1{LkW2NkDDuSByLkSwPUDPxE1uIFfJOVA:OS5{N{mgxtEhOC5zOUSg{txO	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
OSC-19	MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7oW\|RKSzVyPUOuOFgyKMLzIECuPVU{KM7:TTygS2k2OD1zLkO2OkDDuSByLke3NEDPxE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
Cal33	NF7oTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPSR4pLUUN3ME2yMlI5OiEEsTCwMlQzOyEQvF2sJGdKPTB;MT6zOFkhyrFiMD6zOlMh\|ryP	M3jY[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
UM-SCC-22B	M1HZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT6XlNoUUN3ME2yMlY1QCEEsTCwMlU1OiEQvF2sJGdKPTB;MT6zNlAhyrFiMD6yNFQh\|ryP	NH;KfIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
UM-SCC-17B	MlHQSpVv[3Srb36gRZN{[Xl?	MkD1NE0{OCEQvF2=	NGfjfXMxNTJ2IHi=		MVvpcohq[mm2czDTWGFVOyCjY4TpeoF1cW:wIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?	NFLqOlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
OSC-19	NF;xZ3BHfW6ldHnvckBCe3OjeR?=	MUmwMVMxKM7:TR?=	NVXLfYVQOC1{NDDo		MV7pcohq[mm2czDTWGFVOyCjY4TpeoF1cW:wIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?	M4\rVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
Cal33	M2DvOmZ2dmO2aX;uJGF{e2G7	M3XNVFAuOzBizszN	NIn3OJAxNTJ2IHi=		NX;MZ2lVcW6qaXLpeJMhW1SDVEOgZYN1cX[jdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	NEjkTG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
UM-SCC-22B	NGnE[3BHfW6ldHnvckBCe3OjeR?=	MYWwMVMxKM7:TR?=	Mlr2NE0zPCCq		NFTpSlRqdmirYnn0d{BUXEGWMzDhZ5RqfmG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{C4PVkoRjJ{N{ewPFk6RC:jPh?=
U-87MG	NUHiT2xXS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGCyeHQxNTFyIN88US=>	NVzEZWV5PzJiaB?=	NU[yT2tqTE2VTx?=	MVzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NH:2fZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOlY5Oid-MkW0N\|Y3QDJ:L3G+
U-373MG	NXW0Soc1S2WubDDWbYFjcWyrdImgRZN{[Xl?	NH7jO3gxNTFyIN88US=>	NIC2e3M4OiCq	M3fSWmROW09?	NEDFW29qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M3qwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
SH-SY5Y	M{PIVGNmdGxiVnnhZoltcXS7IFHzd4F6	M1XFfFAuOTBizszN	MnXoO\|IhcA>?	MVXEUXNQ	MUnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	Mmm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
Tu-9648	NXmwRW83S2WubDDWbYFjcWyrdImgRZN{[Xl?	Mn7ONE0yOCEQvF2=	Mn3uO\|IhcA>?	M2XSV2ROW09?	NX\WPIR1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NWnUVoRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Y3QDJpPkK1OFM3Pjh{PD;hQi=>
Neuro-2a	NUi1[mVlS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYmwMVExKM7:TR?=	NHjpOoE4OiCq	MoS3SG1UVw>?	NUTtbFB2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M2DENFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
PCNs	MmDLR4VtdCCYaXHibYxqfHliQYPzZZk>	M2PNO\|AuOTBizszN	NVXSc5JlPzJiaB?=	M{LabmROW09?	NEi1UWJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NF75SWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOlY5Oid-MkW0N\|Y3QDJ:L3G+
PGCs	M2PFSGNmdGxiVnnhZoltcXS7IFHzd4F6	NFm0UZMxNTFyIN88US=>	MkCyO\|IhcA>?	MWHEUXNQ	M{HMSYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	Ml3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
RAW264.7	MnPtSpVv[3Srb36gRZN{[Xl?	NUTDSYN{OTBizszN	M2LYRlEzKGh?		MlvDZYJzd2ejdHXzJJRp\SCvUl7BJIV5eHKnc4Ppc45{KG:oIFrBT\|ItKFOWQWSxMEBUXEGWMjygZY5lKFOWQWSzJIlv\HWlZXSgZpkhTE:QIHHu[EBVNTJidH;4bY4>	NEXjRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS1OFQ{OSd-MkK0OVQ1OzF:L3G+
RAW264.7	M4rIRmFxd3C2b4Ppd{BCe3OjeR?=	M3vUPFUwOTBizszN	NYOy[mVKPDVibXnu		MYTlcohidmOnczD0c5hqdnNiaX7keYNm\CCjcH;weI9{cXNiYX7kJG1OWCCub4Pz	NYi0b3F2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OVQ1OzFpPkKyOFU1PDNzPD;hQi=>
SW480	M17VNWNmdGxiVnnhZoltcXS7IFHzd4F6	MUO1M\|ExNzJyIN88US=>	NU\FbFVyPzJiaB?=		Mo\CbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlib3[geIhmKEGORFirM2NFOTN\|K9MgZ4VtdHN?	M4W2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUCwN\|k4Lz5{MUmwNFM6PzxxYU6=
HCT116	NIDCOYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MnvyOU8yOC9{MDFOwG0>	M2fJUVczKGh?		NE\YfYtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDv[kB1cGViQVzETEswS0RzM{OrxsBk\Wyucx?=	MofTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MECzPVcoRjJzOUCwN\|k4RC:jPh?=
DLD-1	NY\SdZlCS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlfpOU8yOC9{MDFOwG0>	M4[3XlczKGh?		NWLCSo1jcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgc4YhfGinIFHMSGgsN0OGMUOzL:Kh[2WubIO=	NV7HeYx7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NFA{QTdpPkKxPVAxOzl5PD;hQi=>
SNU387	NUTHeJNRS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mln2NlDDqM7:TdMg	MXSyOEBp		NXjPT3JsemWmdXPld{Bk\WyuII\pZYJqdGm2eR?=	Mn7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUG5O\|UoRjJzM{GxPVc2RC:jPh?=
SNU398	NGnQO3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MknBNlDDqM7:TdMg	M1:0SFI1KGh?		NH3PbGxz\WS3Y3XzJINmdGxidnnhZoltcXS7	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzMUm3OUc,OjF\|MUG5O\|U9N2F-
HepG2	MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NY\kUZVHOjEEoN88UeKh	M2HldFI1KGh?		NH\xb5hz\WS3Y3XzJINmdGxidnnhZoltcXS7	NXPuO5ZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVE6PzVpPkKxN\|EyQTd3PD;hQi=>
Huh-7	NF3rSIlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3HzdFIxyqEQvF5CpC=>	NIDUTVczPCCq		MXny[YR2[2W\|IHPlcIwhfmmjYnnsbZR6	NGTSc5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxNVk4PSd-MkGzNVE6PzV:L3G+
VSMC	M2Xofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XIVFMwPS9zMDFOwG0>	NIrtfow{OCCvaX6=	MmXzSG1UVw>?	MW\wdoV3\W62czDQSGdHNSCjbnSgeIhzd22kaX6tcYVlcWG2ZXSgWnNOSyCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYL0eXVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OFc{ODZpPkKwPFQ4OzB4PD;hQi=>
MDA-MB-231	NGLuOIxCeG:ydH;zbZMhSXO\|YYm=	M1vlPVExKM7:TR?=	MX2yOEBp	MoXLSG1UV8Li	NYTsdYU6cW6mdXPld{BieG:ydH;zbZM>	NFLQfoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GxOFAxPSd-MUexNVQxODV:L3G+
MDA-MB-435S	NXLK[3M3SXCxcITvd4l{KEG\|c3H5	MWSxNEDPxE1?	Mkj1NlQhcA>?	M3j1T2ROW00EoB?=	NVzxTpNIcW6mdXPld{BieG:ydH;zbZM>	NIqzR3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GxOFAxPSd-MUexNVQxODV:L3G+
AsPC1	NYrtXYpXSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1rnXVczKGi{cx?=		M3;6fGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQYPQR\|Eh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEGuN\|Ih\|ryPLh?=	NGrMS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pid-MkS5NFQ6PjZ:L3G+
MDA-MB-231	M2PPOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NX\IdVA2PzJiaILz		M1HOdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSXIudmWpYYTpeoUh[W6mIITybZBt\S2wZXfheIl3\SCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCyMlg6KM7:TT6=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MCF7	M2HyXmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYe3NkBpenN?		MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFXSMZBwe2m2aY\lJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEOuOkDPxE1w	M2DWflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC0PVY3Lz5{NEmwOFk3PjxxYU6=
PANC1	MnvjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHrHb\|M4OiCqcoO=		MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCDTlOxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB\|Lke3JO69VS5?	M3rUN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC0PVY3Lz5{NEmwOFk3PjxxYU6=
MDA-MB-231	MnHjR5l1d3SxeHnjbZR6KGG\|c3H5		Mmj3OFghcHK\|		MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlU3KM7:TT6=	NITtc5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
MDA-MB-435S	MmLSR5l1d3SxeHnjbZR6KGG\|c3H5		MojZOFghcHK\|		NXzJfWt[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PVNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwOEeg{txONg>?	NFXWOZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
MCF7	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=		M1uzSFQ5KGi{cx?=		MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjF4IN88UU4>	M1XBbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2Olg6Lz5{NkO5OlY5QTxxYU6=
A549	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		MX60PEBpenN?		MmXPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi53IN88UU4>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4PUc,OjZ\|OU[2PFk9N2F-
DU145	NULGO3Y2S3m2b4TvfIlkcXS7IHHzd4F6		M1H5NlQ5KGi{cx?=		MmXpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwNTFOwG0v	NXLBeWIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
PANC1	NVjGSHNOS3m2b4TvfIlkcXS7IHHzd4F6		M1znTVQ5KGi{cx?=		MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRW5EOSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi57IN88UU4>	NFHpfIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
HCT116	MlmzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV3hO\|hGPzJiaILz		NULXbZBKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvODhizszNMi=>	NELxSHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exPFQ4OCd-Mke3NVg1PzB:L3G+
MDA-MB-231	NUXKVIZWSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFfkVXQ4OiCqcoO=		Ml\zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyNjZ6IN88UU4>	NEHnbXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exPFQ4OCd-Mke3NVg1PzB:L3G+
MCF7	NVnQdoY2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NF63Z2k4OiCqcoO=		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwM{[g{txONg>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzOES3NEc,Ojd5MUi0O\|A9N2F-
A549	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4TjSVczKGi{cx?=		MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwNDFOwG0v	NIXzV2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exPFQ4OCd-Mke3NVg1PzB:L3G+
AD293	NXnNV2ozTnWwY4Tpc44h[XO\|YYm=		M{nO[VYhcHK\|		NV;QU29MUW6qaXLpeIlwdiCxZjDJSm5o[W2vYT3zeIlufWyjdHXkJGdHWC:ITFHHMZRi\2enZDDTWGFVOyCmaX3ldol7[XSrb36gbY4hcHWvYX6gRWQzQTNiY3XscJMhcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMtKEmFNUCgQUA2NjFizszNMi=>	Mo\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkiwNFAoRjNyMkK4NFAxRC:jPh?=
MDA-MB-231	MkfOSpVv[3Srb36gZZN{[Xl?	MUixJJRwKDFyIIXN	MXmxNkBpenN?		MlH6TY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhXHm{N{C1JIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhf2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NFrzd4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pid-MkS5NFQ6PjZ:L3G+
MDA-MB-231	NFnjdo1CdnSrY3HuZ4VzKGG\|c3H5	M2jpd\|EhfG9iMUCgeW0>	Mki1OFghcHK\|		MVzBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vNCCjcH;weI9{cXNiYX7kJINmdGy3bHHyJI1wenCqb3zv[4lk[WxiY3jhcodmeyCjdDCxJJRwKDFyIIXNJIFnfGW{IES4JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7	M4HofVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC0PVY3Lz5{NEmwOFk3PjxxYU6=
MDA-MB-231	MmTpSpVv[3Srb36gZZN{[Xl?	MoP6NUB1dyBzMDD1US=>	NUXOdGpiOTJiaILz		MmjQSIVkemWjc3WgbY4hW1SDVEOgdJJwfGWrbjDlfJBz\XO\|aX;uJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhf2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MCF7	NE\kdXlHfW6ldHnvckBie3OjeR?=		NHPweVcyOiCqcoO=		MYHJcohq[mm2aX;uJI9nKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEB[PzB3IHnuJIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NGP6W489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
MDA-MB-435S	M{PxV2Z2dmO2aX;uJIF{e2G7		NX7MTZpMOTJiaILz		MlfhTY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDpckBpfW2jbjDNSGEuVUJvNEO1V{Bk\WyuczDh[pRmeiBzMjDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NG\acJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
MDA-MB-231	M3ewXGZ2dmO2aX;uJIF{e2G7		NFfo[3IyOiCqcoO=		NWnGOm4xUW6qaXLpeIlwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OU[2PFkoRjJ4M{m2Olg6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 ; PubMed: 25261365 Oncotarget (A) PC3M-1E8 cells were treated with different doses of Stattic for 4 h. (B) PC3M-1E8 cells were treated with 10 μM Stattic for different time points. Survivin / c-Myc / Bcl-xl ; PubMed: 25261365 Oncotarget Western blot analysis of STAT3 downstream targets in PC3M-1E8 cells treated with 10 μM Stattic for 24 h. PARP / C-PARP / Caspase-3 / C-Caspse-3 ; PubMed: 23382914 PLoS One NPC cells were exposed to the indicated concentrations of Stattic for 48 h; apoptotic cells were measured by western blot analysis of cleaved PARP and cleaved caspase-3. Protein levels were quantified using ImageJ software.	25261365 23382914
Immunofluorescence	p-STAT3 / STAT3 / Survivin ; PubMed: 25261365 Oncotarget Cellular localization of pSTAT3 and survivin (green) was observed by confocal microscopy after immunofluorescent staining of PC3M-1E8 cancer cells treated with 10 μM Stattic.	25261365
Growth inhibition assay	Cell viability; PubMed: 23382914 PLoS One Stattic inhibits the cell viability of NPC cells in a time-dependent manner. CNE2 cells were treated with 8 µM Stattic for the indicated times, and cell viability was measured by the MTT assay.	23382914
ELISA	BDNF; PubMed: 27456333 Sci Rep BDNF secretion was analyzed using ELISA in A549 and H1299 cells treated with or without Stattic. Results are shown as the mean ± S.E. n = 3; *p < 0.05, vs Control group, Student’s t-test.	27456333

激酶实验： ^[1]	- 合并高通量筛选和荧光偏振检测: 在约30°C下进行筛选。通过实验化合物与STAT1, STAT5, 和 Lck 的SH2结构域结合的类似实验验证筛选的特异性。所有FP实验的Buffer组分的终浓度为10 mM HEPES(pH 7.5),1 mM EDTA,0.1% Nonidet P-40,50 mM NaCl,和10% DMSO。二硫苏糖醇的存在对抑制活性是必不可少的。肽序列为:STAT3,5-carboxyfluorescein-GY(PO₃H₂)LPQTV-NH2; STAT1, 5-carboxyfluorescein-GY(PO₃H₂)DKPHVL;STAT5, 5-carboxyfluorescein-GY(PO₃H₂)LVLDKW; 和 Lck, 5-carboxyfluorescein-GY(PO₃H₂)EEIP。在 30°C下进行特异性分析, 使用150 nM蛋白(STAT1,STAT3,和STAT5)。在37°C下进行分析，使用370 nM 蛋白(STAT3)或100 nM蛋白 (Lck)。蛋白与实验化合物在Eppendorf管中在指定温度环境下温育60分钟，然后加入相应的5-carboxyfluorescein标记的肽（终浓度为10 nM）。混合物至少平衡30分钟，然后在室温下测量。实验化合物在20×stock在DMSO中稀释到指定浓度。使用 SigmaPlot绘制结合曲线和抑制曲线。独立实验中，所有竞争曲线都需重复三次。
细胞实验： ^[2]	- 合并 Cell lines: Ly3细胞 Concentrations: ~2.5 μM Incubation Time: 48小时 Method: MTS (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: Ly3亲本NOD/SCID IL2R移植瘤 Dosages: 每天3.75 mg/kg Administration: 瘤内注射 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	42 mg/mL (198.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Stattic SDF

分子量	211.19
化学式	C₈H₅NO₄S
CAS号	19983-44-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to dissolve the compound for i.p. injection, could you give me some suggestions?
回答：
S7024 Stattic can be dissolved in 2% DMSO/PEG 300/dd H2O at 8 mg/mL as a clear solution.

研究领域

产品类型

定制您的化合物库

Stattic

客户使用Selleck生产的Stattic发表文献184篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Stattic SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品